Impact of Rotavirus Vaccine Introduction for South Australian Children
NCT01472575 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2011-11-16
Summary
This project aims to assess the impact of rotavirus vaccine introduction on severe gastroenteritis in South Australian children. Prevalence of rotavirus coded hospitalisations and all-cause gastroenteritis hospitalisations will be compared for a two year period prior to introduction of the vaccine and a two year period following introduction of the vaccine. Severity of rotavirus coded admissions during the periods will also be assessed.
Hypotheses:
1. Introduction of the rotavirus vaccine will result in an 80% reduction in hospitalisations for rotavirus positive gastroenteritis (ICD code A0.80) in children less than two years of age.
2. Introduction of rotavirus vaccine will result in an 80% reduction in Paediatric Emergency presentations for rotavirus positive gastroenteritis in children under two years of age.
3. Introduction of the rotavirus vaccine will result in a 50% reduction in hospitalisations for all cause gastroenteritis (ICD codes A0.00-A0.90) in children less than two years of age.
4. Introduction of the rotavirus vaccine will result in a 50% reduction in Paediatric Emergency presentations for all cause gastroenteritis in children less than two years of age.
5. Introduction of rotavirus vaccine will result in a reduction in hospitalisation and Paediatric Emergency presentations in children aged four and five years with rotavirus positive gastroenteritis (unvaccinated cohort).
6. There will be no difference in severity of disease as scored by the Vesikari and/or clark severity score prior to and post introduction of rotavirus vaccine
Conditions
- Viral Gastroenteritis Due to Rotavirus
- Gastroenteritis
Sponsors & Collaborators
- collaborator INDUSTRY
-
Associate Professor Helen Marshall
lead OTHER_GOV
Principal Investigators
-
Helen S Marshall, MBBS MD MPH · Women's and Children's Health Network
Eligibility
- Max Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2011-12-31
- Completion
- 2011-12-31
Countries
- Australia
Study Locations
More Related Trials
-
Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants
NCT00655187 ·Status: COMPLETED
-
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
NCT04658914 ·Status: COMPLETED ·Phase: PHASE2
-
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
NCT01363726 ·Status: UNKNOWN
-
The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines
NCT02662543 ·Status: UNKNOWN
-
Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)
NCT01633190 ·Status: UNKNOWN
-
Optimising Rotavirus Vaccine in Aboriginal Children
NCT02941107 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological Study
NCT03271593 ·Status: COMPLETED
-
Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden
NCT00489567 ·Status: COMPLETED
-
ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage
NCT06882070 ·Status: COMPLETED
-
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
NCT03483116 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine
NCT01738074 ·Status: UNKNOWN ·Phase: PHASE3
-
Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)
NCT00329745 ·Status: COMPLETED ·Phase: PHASE3
-
Improving Rotavirus Vaccine Immune Response
NCT01825109 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana
NCT01575197 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis
NCT01978223 ·Status: WITHDRAWN
-
Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.
NCT00740935 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E
NCT01305109 ·Status: UNKNOWN ·Phase: PHASE3
-
Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).
NCT01195844 ·Status: TERMINATED
-
Effectiveness of Monovalent Rotavirus Vaccine (RV1)
NCT01871038 ·Status: COMPLETED
-
Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model
NCT04123119 ·Status: COMPLETED ·Phase: NA
-
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination
NCT01682005 ·Status: COMPLETED
-
To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus
NCT04819412 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™
NCT01435967 ·Status: COMPLETED
-
The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants
NCT06200844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination
NCT01915888 ·Status: COMPLETED